Abstract
Leukocytapheresis (LCAP) is a method of therapeutic apheresis to remove patients’ peripheral leukocytes by extracorporeal circulation. Previous studies showed that LCAP for the treatment of ulcerative colitis (UC) was more effective and had fewer adverse effects compared to high-dose steroid therapy. However, there are no reports on the application of LCAP for UC patients with toxic megacolon (TM). This study reports the effectiveness and safety of LCAP in treating patients with severe or fulminant UC with TM. Six patients were enrolled in this study and LCAP sessions were performed three times per week for 2 weeks, followed by four further times in the next 4 weeks. After completion of therapy, four patients improved in TM and went into the remission stage of UC. The average Rachmilewitz clinical activity index of these four patients improved from 19.5 to 1. The remaining two patients had to undergo colectomy, however, the symptoms had been mitigated by LCAP and the operations were completed without any problems. These results suggest that LCAP is an additional effective and safe option for TM management in preventing colectomy or for bridging to a safer operation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Gan SI, Beck PL: A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 98:2363–2371, 2003
Sheth SG, LaMont JT: Toxic megacolon. Lancet 351:509–513, 1998
LaMont JT, Kandel GP: Toxic megacolon in ulcerative colitis. Early diagnosis and management. Hosp Pract (Off Ed) 1986:21
Panos MZ, Wood MJ, Asquith P: Toxic megacolon: the knee-elbow position relieves bowel distension. Gut 34:1726–1727, 1993
Present DH, Wolfson D, Gelernt IM, et al.: Medical decompression of toxic megacolon by “rolling.” A new technique of decompression with favorable long-term follow-up. J Clin Gastroenterol 10:485–490, 1988
Riedler L, Wohlgenannt D, Stoss F, et al.: Endoscopic decompression in “toxic megacolon.” Surg Endosc 3:51–53, 1989
Welfare MR, Barton JR, Cobden I: Hyperbaric oxygen for toxic megacolon. Lancet 353:70–71, 1999
Momoshima S, Kohda E, Hiramatsu K, Asakura H: Intra-arterial prednisolone infusion therapy in ulcerative colitis. AJR 145:1057–1060, 1985
Truelove SC, Marks CG: Toxic megacolon. Part I: Pathogenesis, diagnosis and treatment. Clin Gastroenterol 10:107–117, 1981
Actis GC, Ottobrelli A, Pera A, et al.: Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol 17:10–13, 1993
Pascu M, Muller AR, Wiedenmann B, Dignass AU: Rescue therapy with tacrolimus in a patient with toxic megacolon. Int J Colorectal Dis 18:271–275, 2003
Hartong WA, Arvanitakis C, Skibba RM, Klotz AP: Treatment of toxic megacolon. A comparative review of 29 patients. Am J Dig Dis 22:195–200, 1977
Grieco MB, Bordan DL, Geiss AC, Beil AR Jr: Toxic megacolon complicating Crohn’s colitis. Ann Surg 191:75–80, 1980
Sawada K, Ohnishi K, Fukui S, et al.: Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 30:322–329, 1995
Sawada K, Ohnishi K, Kosaka T, et al.: Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apheresis 1:207–211, 1997
Sawada K, Muto T, Shimoyama T, et al.: Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Cur Pharm Design 9:307–321, 2003
Sawada K: Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease. Dis Colon Rectum 46:S66–S77, 2003
Shibata H, Kuriyama T, Yamawaki N: Cellsorba. Ther Apher Dial 7:44–47, 2003
Aoyama T, Ino Y, Ozeki M, et al.: Pharmacological studies of FUT-175, Nafamostat Mesilate. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 35:203–227, 1984
Rachmilewitz D: On behalf of an international study group (Israel). Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J 298:82–86, 1989
Matts SGF: The value of rectal biopsy in the diagnosis of ulcerative colitis. Quart J Med 393–400, 1961
Obayashi T, Tamura H, Tanaka S, et al.: Removal of limulus test interfering factors in blood samples with perchloric acid and the improvement of the specificity of the limulus test by fractionating amebocyte lysate. Prog Clin Biol Res 231:357–369, 1987
Shimoyama T, Sawada K, Hiwatashi N, et al.: Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: A multicenter study. J Clin Apheresis 16:1–9, 2001
Hanai H, Watanabe F, Saniabadi A, et al.: Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 47:2349–2353, 2002
Hanai H, Watanabe F, Takeuchi K, et al.: Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 1:28–35, 2003
Kosaka T, Sawada K, Ohnishi K, et al.: Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn’s disease. Intern Med 38:102–111, 1999
Hidaka T, Suzuki K, Matsuki Y, et al.: Filtration leukocytapheresis therapy in rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial. Arth Rheum 42:431–437, 1999
Fujimori J, Yoshino S: Improvement in rheumatoid arthritis following application of a granulotrap column, G-1. Rheumatol Int 15:175–180, 1996
Ohara M, Saniabadi AR, Kokuma S, et al.: Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 21:989–994, 1997
Ueki Y, Yamasaki S, Kanamoto Y, et al.: Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis. Rheumatology (Oxford) 39:165–171, 2000
Furuta T, Hotta O, Yusa N, Horigome I, Chiba S, Taguma Y: Lymphocytapheresis to treat rapidly progressive glomerulonephritis: a randomised comparison with steroid-pulse treatment. Lancet 352:203–204, 1998
Hidaka T, Suzuki K, Kawakami M, et al.: Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J Clin Apheresis 16:74–81, 2001
McCarthy DA, Rampton DS, Liu Y-C: Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 86:489–493, 1991
Meuret G, Bitzi A, Hammer B: Macrophage turnover in Crohn’s disease and ulcerative colitis. Gastroenterology 74:501–503, 1978
Allison MC, Dhillon AP, Lewis WG, Pounder RE (eds): Inflammatory Bowel Disease. London, Mosby, 1998, pp 91–95
Tibble JA, Sigthorsson G, Bridger D, Fagerhol MK, Bjarnason I: Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119:15–22, 2000
Podolsky DK: Inflammatory bowel disease. N Engl J Med 347:417–429, 2002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sawada, K., Egashira, A., Ohnishi, K. et al. Leukocytapheresis (LCAP) for Management of Fulminant Ulcerative Colitis with Toxic Megacolon. Dig Dis Sci 50, 767–773 (2005). https://doi.org/10.1007/s10620-005-2571-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10620-005-2571-3